Phaseline

Companies › Neurogene

Neurogene: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Metabolic and endocrine, Neurology; next expected readout Nov 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NGN-401
Recombinant AAV9 carrying full-length human MECP2 transgene
MECP2Phase 3Rett SyndromeDec 2029
NGN-101
Gene therapy for CLN5 deficiency delivered via intracerebroventricular and intravitreal in
CLN5Phase 1Neuronal Ceroid Lipofuscinosis CLN5Nov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05228145NGN-101Phase 1Neuronal Ceroid Lipofuscinosis CLN5Metabolic and endocrineNov 2028
NCT05898620NGN-401Phase 3Rett SyndromeNeurologyDec 2029

From the company's SEC filings

Cash and short-term investments of $360m on 2026-09-30; operating cash outflow about $106m a year; runway about 41 months at that burn, to Feb 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CLN5 (1) MECP2 (1)

Companies with the same targets

Taysha Gene Therapies Ionis Pharmaceuticals

Companies built like this

REGENXBIO Taysha Gene Therapies AskBio Elpida Therapeutics SPC NeuroPace

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.